|
1
|
Kanda M and Kodera Y: Recent advances in
the molecular diagnostics of gastric cancer. World J Gastroenterol.
21:9838–9852. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim JH, Kim SS, Lee JH, Jung DH, Cheung
DY, Chung WC and Park SH: Early detection is important to reduce
the economic burden of gastric cancer. J Gastric Cancer. 18:82–89.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee HS, Jeon SW, Nomura S, Seto Y, Kwon
YH, Nam SY, Ishibashi Y, Ohtsu H, Ohmoto Y and Yang HM: Screening
biomarker as an alternative to endoscopy for the detection of early
gastric cancer: The combination of serum trefoil factor family 3
and pepsinogen. Gastroenterol Res Pract. 2018:10240742018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Majeed W, Iftikhar A, Khaliq T, Aslam B,
Muzaffar H, Atta K, Mahmood A and Waris S: Gastric carcinoma:
Recent trends in diagnostic biomarkers and molecular targeted
therapies. Asian Pac J Cancer Prev. 17:3053–3060. 2016.PubMed/NCBI
|
|
6
|
Feng F, Tian Y, Xu G, Liu Z, Liu S, Zheng
G, Guo M, Lian X, Fan D and Zhang H: Diagnostic and prognostic
value of CEA, CA19-9, AFP and CA125 for early gastric cancer. BMC
Cancer. 17:7372017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jin Z, Jiang W and Wang L: Biomarkers for
gastric cancer: Progression in early diagnosis and prognosis
(Review). Oncol Lett. 9:1502–1508. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Oh IS, Shimizu H, Satoh T, Okada S, Adachi
S, Inoue K, Eguchi H, Yamamoto M, Imaki T, Hashimoto K, et al:
Identification of nesfatin-1 as a satiety molecule in the
hypothalamus. Nature. 443:709–712. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pan W, Hsuchou H and Kastin AJ: Nesfatin-1
crosses the blood-brain barrier without saturation. Peptides.
28:2223–2228. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim J, Chung Y, Kim H, Im E, Lee H and
Yang H: The tissue distribution of Nesfatin-1/NUCB2 in mouse. Dev
Reprod. 18:301–309. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stengel A, Goebel M, Yakubov I, Wang L,
Witcher D, Coskun T, Taché Y, Sachs G and Lambrecht NW:
Identification and characterization of nesfatin-1 immunoreactivity
in endocrine cell types of the rat gastric oxyntic mucosa.
Endocrinology. 150:232–238. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang N, Li J, Wang H, Xiao L, Wei Y, He J
and Wang G: The level of Nesfatin-1 in a mouse gastric cancer model
and its role in gastric cancer comorbid with depression. Shanghai
Arch Psychiatry. 30:119–126. 2018.PubMed/NCBI
|
|
13
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li Z, Xu G, Li Y, Zhao J, Mulholland MW
and Zhang W: mTOR-dependent modulation of gastric nesfatin-1/NUCB2.
Cell Physiol Biochem. 29:493–500. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Paquette M, El-Houjeiri L and Pause A:
mTOR pathways in cancer and autophagy. Cancers (Basel). 10:E182018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li LT, Jiang G, Chen Q and Zheng JN:
Ki67is a promising molecular target in the diagnosis of cancer
(Review). Mol Med Rep. 11:1566–1572. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen L, Li X, Wang GL, Wang Y, Zhu YY and
Zhu J: Clinicopathological significance of overexpression of
TSPAN1, Ki67 and CD34 in gastric carcinoma. Tumori. 94:531–538.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tzanakis NE, Peros G, Karakitsos P,
Giannopoulos GA, Efstathiou SP, Rallis G, Tsigris C, Kostakis A and
Nikiteas NI: Prognostic significance of p53 and Ki67 proteins
expression in Greek gastric cancer patients. Acta Chir Belg.
109:606–611. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Badary DM, Abdel-Wanis ME, Hafez MZ and
Aboulhagag NA: Immunohistochemical analysis of PTEN, HER2/neu, and
ki67 expression in patients with gastric cancer and their
association with survival. Pathophysiology. 24:99–106. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Okines A, Verheij M, Allum W, Cunningham D
and Cervantes A; ESMO Guidelines Working Group, : Gastric cancer:
ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 21 (Suppl 5):v50–v54. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chae S, Lee A and Lee JH: The
effectiveness of the new (7th) UICC N classification in the
prognosis evaluation of gastric cancer patients: A comparative
study between the 5th/6th and 7th UICC N classification. Gastric
Cancer. 14:166–171. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang JY, Li D, Zhang Y, Guan BX, Gao P,
Zhou XC and Zhou CJ: The expression of MCM7 is a useful biomarker
in the early diagnostic of gastric cancer. Pathol Oncol Res.
24:367–372. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang MF, Zhang ZY, Fu J, Yang YF and Yun
JP: Correlation between expression of p53, p21/WAF1, and MDM2
proteins and their prognostic significance in primary
hepatocellular carcinoma. J Transl Med. 7:1102009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gadbail AR, Chaudhary MS, Sarode SC,
Gawande M, Korde S, Tekade SA, Gondivkar S, Hande A and Maladhari
R: Ki67, CD105, and α-SMA expressions better relate the binary oral
epithelial dysplasia grading system of World Health Organization. J
Oral Pathol Med. 46:921–927. 2017.PubMed/NCBI
|
|
25
|
Gadbail AR, Chaudhary MS, Sarode SC,
Gondivkar SM, Belekar L, Mankar-Gadbail MP, Dande R, Tekade SA,
Yuwanati MB and Patil S: Ki67, CD105 and α-smooth muscle actin
expression in disease progression model of oral submucous fibrosis.
J Investig Clin Dent. 10:e124432019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Casasola SV, Colunga MJM, Millán OA and
Martínez Rodríguez JM: Pronostic value of clinicopathologic factors
Ki67, cyclin D1, cyclin D3 and CDK4 in gastric carcinoma.
Oncología. 27:31–37. 2004.
|
|
27
|
Chen Z, Xu YY, Ge JF and Chen FH: CRHR1
mediates the Up-regulation of Synapsin I induced by Nesfatin-1
through ERK1/2 signaling in SH-SY5Y cells. Cell Mol Neurobiol.
38:627–633. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu Y, Pang X, Dong M, Wen F and Zhang Y:
Nesfatin-1 inhibits ovarian epithelial carcinoma cell proliferation
in vitro. Biochem Biophys Res Commun. 440:467–472. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Suzuki S, Takagi K, Miki Y, Onodera Y,
Akahira J, Ebata A, Ishida T, Watanabe M, Sasano H and Suzuki T:
Nucleobindin 2 in human breast carcinoma as a potent prognostic
factor. Cancer Sci. 103:136–143. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cetinkaya H, Karagöz B, Bilgi O, Ozgün A,
Tuncel T, Emirzeoğlu L, Top C and Kandemir EG: Nesfatin-1 in
advanced lung cancer patients with weight loss. Regul Pept.
181:1–3. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kan JY, Yen MC, Wang JY, Wu DC, Chiu YJ,
Ho YW and Kuo PL: Nesfatin-1/Nucleobindin-2 enhances cell
migration, invasion, and epithelial-mesenchymal transition via
LKB1/AMPK/TORC1/ZEB1 pathways in colon cancer. Oncotarget.
7:31336–31349. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stojcev Z, Matysiak K, Duszewski M and
Banasiewicz T: The role of dietary nutrition in stomach cancer.
Contemp Oncol (Pozn). 17:343–345. 2013.PubMed/NCBI
|
|
33
|
Stengel A, Goebel M, Wang L, Rivier J,
Kobelt P, Mönnikes H, Lambrecht NW and Taché Y: Central nesfatin-1
reduces dark-phase food intake and gastric emptying in rats:
Differential role of corticotropin-releasing factor2 receptor.
Endocrinology. 150:4911–4919. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shimizu H, Oh-I S, Hashimoto K, Nakata M,
Yamamoto S, Yoshida N, Eguchi H, Kato I, Inoue K, Satoh T, et al:
Peripheral administration of nesfatin-1 reduces food intake in
mice: The leptin-independent mechanism. Endocrinology. 150:662–671.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang C, Zhang J, Ding M, Xu K, Li L, Mao L
and Zheng J: Ki67 targeted strategies for cancer therapy. Clin
Transl Oncol. 20:570–575. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhou Y, Li Y, Zheng J, Liu K and Zhang H:
Detecting of gastric cancer by Bcl-2 and Ki67. Int J Clin Exp
Pathol. 8:7287–7290. 2015.PubMed/NCBI
|
|
37
|
Takagi K, Miki Y, Tanaka S, Hashimoto C,
Watanabe M, Sasano H, Ito K and Suzuki T: Nucleobindin 2 (NUCB2) in
human endometrial carcinoma: A potent prognostic factor associated
with cell proliferation and migration. Endocr J. 63:287–299. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shimada H, Noie T, Ohashi M, Oba K and
Takahashi Y: Clinical significance of serum tumor markers for
gastric cancer: A systematic review of literature by the Task Force
of the Japanese Gastric Cancer Association. Gastric Cancer.
17:26–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pectasides D, Mylonakis A, Kostopoulou M,
Papadopoulou M, Triantafillis D, Varthalitis J, Dimitriades M and
Athanassiou A: CEA, CA 19-9, and CA-50 in monitoring gastric
carcinoma. Am J Clin Oncol. 20:348–353. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fan B and Xiong B: Investigation of serum
tumor markers in the diagnosis of gastric cancer.
Hepatogastroenterology. 58:239–245. 2011.PubMed/NCBI
|
|
41
|
Li BS, Zhao YL, Guo G, Li W, Zhu ED, Luo
X, Mao XH, Zou QM, Yu PW, Zuo QF, et al: Plasma microRNAs, miR-223,
miR-21 and miR-218, as Novel Potential Biomarkers for Gastric
Cancer Detection. PLoS One. 7:e416292012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tong W, Ye F, He L, Cui L, Cui M, Hu Y, Li
W, Jiang J, Zhang DY and Suo J: Serum biomarker panels for
diagnosis of gastric cancer. Onco Targets Ther. 26:2455–2463.
2016.
|
|
43
|
Aydin S: Role of NUCB2/nesfatin-1 as a
possible biomarker. Curr Pharm Des. 19:6986–6992. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Başar O, Akbal E, Köklü S, Koçak E, Tuna
Y, Ekiz F, Gültuna S, Yιlmaz FM and Aydoğan T: A novel appetite
peptide, nesfatin-1 in patients with non-alcoholic fatty liver
disease. Scand J Clin Lab Invest. 72:479–483. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xia QR, Liang J, Cao Y, Shan F, Liu Y and
Xu YY: Increased plasma nesfatin-1 levels may be associated with
corticosterone, IL-6, and CRP levels in patients with major
depressive disorder. Clin Chim Acta. 480:107–111. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Aydin S, Dag E, Ozkan Y, Erman F, Dagli
AF, Kilic N, Sahin I, Karatas F, Yoldas T, Barim AO and Kendir Y:
Nesfatin-1 and ghrelin levels in serum and saliva of epileptic
patients: Hormonal changes can have a major effect on seizure
disorders. Mol Cell Biochem. 328:49–56. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ramanjaneya M, Chen J, Brown JE, Tripathi
G, Hallschmid M, Patel S, Kern W, Hillhouse EW, Lehnert H, Tan BK
and Randeva HS: Identification of nesfatin-1 in human and murine
adipose tissue: A novel depot-specific adipokine with increased
levels in obesity. Endocrinology. 151:3169–3180. 2010. View Article : Google Scholar : PubMed/NCBI
|
